BD Announces Launch of UltraScore™ 014 Focused Force PTA Balloon

FRANKLIN LAKES, N.J., April 1, 2019 – BD (Becton, Dickinson and Company), a leading global medical technology company, announced the launch of the UltraScore™ 014 Focused Force PTA Balloon. This marks the first scoring balloon with sheath compatibility as small as 4 French on the U.S. market.

The UltraScore™ Focused Force PTA Balloon is intended to dilate stenoses in the iliac, femoral, ilio-femoral, popliteal, infra-popliteal and renal arteries and for the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistulae. This device is also recommended for post dilatation of balloon expandable stents, self-expanding stents, and stent grafts in the peripheral vasculature. The UltraScore™ Focused Force PTA Balloon is designed to longitudinally fracture plaque at lower inflation pressures compared to standard PTA and may allow for more controlled plaque fracture and less vessel recoil, even in calcified lesions. With the addition of the 0.014” guidewire platform,  UltraScore™ Focused Force PTA Balloon is available in both 0.014” and 0.035” solutions with sizes ranging from 2.0 mm to 8.0 mm in diameter and up to 300 mm in length.

“The deliverability, ease of use and expansion of the vessel with UltraScore™ Focused Force PTA Balloon are excellent,” commented William Bachinsky, MD, FACC, FSCAI, Director, Cardiac and Vascular Interventional Program at UPMC Pinnacle. “The addition of UltraScore™ 014 Focused Force PTA Balloon will fit right in with our treatment algorithms for popliteal and infrapopliteal lesions.”

Both UltraScore™ 035 and UltraScore™ 014 devices are CE-marked and have received 510(k) clearance by the U.S. Food and Drug Administration.

About BD

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of healthcare by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for healthcare providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to healthcare. In 2017, BD welcomed C. R. Bard and its products into the BD family. For more information on BD, please visit